ABEONA THERAPEUTICS INC (ABEO)
US00289Y2063 - Common Stock
We assign a fundamental rating of 3 out of 10 to ABEO. ABEO was compared to 588 industry peers in the Biotechnology industry. While ABEO seems to be doing ok healthwise, there are quite some concerns on its profitability. ABEO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ABEO had negative earnings in the past year.
In the past year ABEO has reported a negative cash flow from operations.
In the past 5 years ABEO always reported negative net income.
ABEO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ABEO has a worse Return On Assets (-84.67%) than 72.70% of its industry peers.
Looking at the Return On Equity, with a value of -365.51%, ABEO is doing worse than 76.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.67% | ||
| ROE | -365.51% | ||
| ROIC | N/A |
ROA(3y)-86.37%
ROA(5y)-69.79%
ROE(3y)-230.99%
ROE(5y)-163.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABEO has more shares outstanding
Compared to 5 years ago, ABEO has more shares outstanding
There is no outstanding debt for ABEO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ABEO has an Altman-Z score of -16.88. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO has a Altman-Z score of -16.88. This is amonst the worse of the industry: ABEO underperforms 85.15% of its industry peers.
ABEO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.88 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
ABEO has a Current Ratio of 4.15. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
ABEO has a Current ratio (4.15) which is comparable to the rest of the industry.
ABEO has a Quick Ratio of 4.15. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.15, ABEO perfoms like the industry average, outperforming 47.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.15 | ||
| Quick Ratio | 4.15 |
3. Growth
3.1 Past
ABEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.99%, which is quite impressive.
The Revenue has grown by 146.48% in the past year. This is a very strong growth!
Measured over the past years, ABEO shows a small growth in Revenue. The Revenue has been growing by 3.13% on average per year.
EPS 1Y (TTM)50.99%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-150.33%
Revenue 1Y (TTM)146.48%
Revenue growth 3Y-29.53%
Revenue growth 5Y3.13%
Revenue growth Q2Q-100%
3.2 Future
ABEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.44% yearly.
Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 141.78% on average per year.
EPS Next Y27.73%
EPS Next 2Y25.94%
EPS Next 3Y32.34%
EPS Next 5Y36.44%
Revenue Next Year410%
Revenue Next 2Y350.71%
Revenue Next 3Y246.49%
Revenue Next 5Y141.78%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ABEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABEO's earnings are expected to grow with 32.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.94%
EPS Next 3Y32.34%
5. Dividend
5.1 Amount
No dividends for ABEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ABEONA THERAPEUTICS INC
NASDAQ:ABEO (4/30/2024, 1:15:46 PM)
4.1
+0.66 (+19.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap112.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.67% | ||
| ROE | -365.51% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.15 | ||
| Quick Ratio | 4.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50.99%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y27.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)146.48%
Revenue growth 3Y-29.53%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y